Cappuzzo F, et al. IMpower131: Final OS results of carboplatin + nab-paclitaxel +/- atezolizumab in advanced squamous NSCLC. Abstract OA14.02. WCLC 7-10 sept. 2019, Barcelona, Spanje.,West H, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):924-37.
Acht fysieke signalen kondigen stervensfase oncologische patiënt aan
feb 2015